Treatment with idecabtagene vicleu-cel consists of autotransfusion of genetically modified lymphocytes. According to one non-comparative trial, this treatment may increase the chances of survival in patients whose general state of health is sufficiently good to tolerate it. Its frequent serious adverse effects, which are often prolonged and sometimes fatal, include haematological disorders, infections, cytokine release syndrome, and neurological disorders. It is a very burdensome and inconvenient treatment for patients. The results of a comparative trial are expected in mid-2023.
展开▼
